Pharmalot

By  Ed Silverman

Taking stock of the drug industry, from the lab to the medicine chest. Sign up for the newsletter here.

Pharmalot

Kentucky probes pharmacy benefit managers for allegedly overcharging state Medicaid

By Ed Silverman

SPRAVATO
Pharmalot

J&J’s new esketamine drug for depression may solve an unmet need, but may not be cost-effective

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: NAFTA deal may hinge on patent protections for drugs; House committee goes after Sacklers

By Ed Silverman

New Opioid Approved - Dsuvia
Pharmalot

FDA panel chair and consumer advocate petition FDA to halt opioid approvals

By Ed Silverman

Pharmalot

Pharmalittle: Biogen and Eisai halt Alzheimer’s drug trials; FDA allows sale of some blood pressure drugs in shortage

By Ed Silverman and Elizabeth Cooney

Syringes of the opioid painkiller fentanyl.
Pharmalot

Did a medical education course for doctors harbor a bias in favor of fentanyl products?

By Ed Silverman

Humira
Pharmalot

AbbVie is sued for using Humira patent deals to block competition in the U.S.

By Ed Silverman

Pharmalot

Pharmalittle: Pfizer pays $636 million for rights to gene therapies; Novartis denies bribing Greek officials

By Ed Silverman

Prescription Bottles
Pharmalot

Catalyst says its pricey rare disease drug is doing ‘better than expected’ despite patient anger

By Ed Silverman

Optum
Pharmalot

Amid probe into PBMs, Ohio sues OptumRx for $16 million, and the AG says ‘there’s a storm a-comin’’

By Ed Silverman

Pharmalot

Pharmalittle: Bristol and Starboard duel over Celgene deal; one in five adults ask doctors for cheaper meds

By Ed Silverman

Medicine
Pharmalot

Chile takes several ‘unorthodox’ steps to push back on drug prices, angering pharma

By Ed Silverman

Antibiotic Resistance
Pharmalot

Efforts to import drugs from Canada advance at state level, with Florida latest to get in line

By Ed Silverman

Pharmalot

Pharmalittle: Gilead boosts prices by nearly 5 percent; a ‘patient access’ group is really funded by pharma

By Ed Silverman

Vaccines
Pharmalot

Doctors Without Borders blasts coalition working on vaccine development

By Ed Silverman

Seven up
Pharmalot

Senator asks two pharma CEOs to clarify discrepancies in recent testimony about drug samples

By Ed Silverman

Hires
Pharmalot

Up and down the ladder: The latest comings and goings

By Ed Silverman

Pharmalot

Pharmalittle: A debate over using list prices in research; FDA fast-tracks a Purdue opioid overdose drug

By Ed Silverman

Pharmalot

Pharmalittle: Generic chief at Novartis unit leaves; how Ned Sharpless got to the top of the FDA

By Ed Silverman

Insys Therapeutics headquarters
Pharmalot

Insys may go out of business as controversy, fines, and lawsuits intensify

By Ed Silverman

Pharmalot

Pharmalittle: Bristol CEO says Celgene deal is not defensive; FDA approves generic valsartan

By Ed Silverman

Ron Wyden
Pharmalot

Wyden probes a patient advocacy group over its ties to opioid makers

By Ed Silverman

Giulia Grillo
Pharmalot

Why the Italian health minister is pushing for global transparency on drug pricing

By Ed Silverman

Optum
Pharmalot

UnitedHealth will require drug rebates to be paid to consumers

By Ed Silverman

Pharmalot

Pharmalittle: Hospitals struggle to pay for CAR-T therapies; J&J was the opioid ‘kingpin’

By Ed Silverman

Pfizer
Pharmalot

Pfizer pays $975,000 to settle charges over misleading copay coupons

By Ed Silverman

Failure to report clinical trial data can affect future research strategies and patient safety.
Pharmalot

‘Unacceptable secrecy’ surrounds safety warnings by pharma and regulators in Australia

By Ed Silverman

Bristol-Myers Squibb
Pharmalot

Bristol scrambles to push Celgene deal, but are the odds as high as some think?

By Ed Silverman

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy